Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T1695 versus ciclosporin for moderate to severe vernal keratoconjunctivitis
2025-521567-12-00Phase 2Authorised
- Sponsor
- Laboratoires Théa
- Start
- Nov 2025
- Modality
- Small Molecules, Peptides
- Countries
- 6
01
Overview
Phase 2, randomised trial in Vernal Keratoconjunctivitis (VKC) comparing T1695 arm with Verkazia arm (2 arms). Primary endpoint: Change from baseline at Day 29 in corneal fluorescein staining. Planned start Nov 2025; status: authorised.
02
Drugs
T1695cyclosporine
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on 2025-521567-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521567-12-00.